Trading Signals: NVAX Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Fri. Dec. 22, 2023)(Novavax, Inc.)
| NVAX latest price $41.4000 (3.5%) ($40.0000 - $41.8000) on Fri. Jul. 13, 2012. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 3.1% (three month average) | | RSI | 98 | | Latest Price | $41.4000(3.5%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | NVAX advances 1.7% a day on average for past five trading days. | | Weekly Trend | NVAX advances 17.7% a week on average for past two weeks. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support NVAX advance at 0% a week (0% probability)
EEM(12%) IWM(12%) FXI(11%) EWI(10%) EWJ(10%) | | Factors Impacting NVAX price | NVAX will decline at least -1.55% in a week (0% probabilities).
TLT(-3%) LQD(-2%) XLU(-1%) TIP(-1%) SHY(0%) | | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.55% (StdDev 3.1%) | | Hourly BBV | 0 () | | Intraday Trend | 2% | | | | | |
|
| 5 Day Moving Average | $39.96(3.6%) | | 10 Day Moving Average | $37.49(10.43%) | | 20 Day Moving Average | $32.51(27.35%) | | To recent high | 0% | | To recent low | 78.4% | | Market Cap | $2.534b | | | | | | |
Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.JUL 7, 2020 Shares of NVAX surged more than 40% on the news ts has received $1.6 to develop and to deliver up to 100 million doses of the company’s late-stage Covid-19 vaccine candidate as part of the U.S. government’s Operation Warp Speed program.
The vaccine, which focuses on boosting the body’s immune system to effectively combat a Covid-19 infection, is currently in phase 1 and phase 2 clinical trials in Australia, with preliminary results expected at the end of this month. |